RxDoctor Payments Data

Francessca Glynn, MD

Internal Medicine · Midlothian, VANPI 1063474690

Payments from drug & device makers

$7,840in general payments, 2019–2025

Across 488 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$638
  • Novo Nordisk$636
  • Amgen$530
  • Lilly USA, LLC$490
  • Boehringer Ingelheim$368
  • plus $4K from 52 others

What the payments were for

  • Food & beverage$7,834100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)81$1,118
AstraZeneca30$638
Novo Nordisk45$636
Amgen(2 entities)35$530
Lilly USA, LLC31$490
Boehringer Ingelheim22$368
Pfizer20$304
GSK28$296
Abbott12$273
Merck14$231
Exact Sciences11$210
Sanofi-aventis U.S. LLC9$136
Takeda Pharmaceuticals U.S.A., Inc.8$127
Bayer9$123
Teva Pharmaceuticals USA, Inc.8$123
Dexcom, Inc.6$121
Insightec,inc3$112
Novartis6$111
Biohaven Pharmaceutical Holding Company Ltd.5$110
Esperion Therapeutics, Inc.6$107
Amarin Pharma, Inc.6$105
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$100
Astellas Pharma US Inc6$92
Otsuka America Pharmaceutical, Inc.4$90
Dynavax Technologies Corporation5$90
Corium, LLC5$79
Edwards Lifesciences4$76
Actelion Pharmaceuticals US, Inc.4$76
Biogen4$71
Bausch Health US, LLC3$70
Eisai Inc.4$69
Sumitomo Pharma America, Inc.3$62
Kowa Pharmaceuticals America, Inc.4$57
Medtronic(2 entities)3$54
Shire North American Group Inc4$50
Biohaven Pharmaceuticals, Inc.2$44
Amneal Pharmaceuticals LLC3$42
Genentech USA, Inc.3$39
Johnson & Johnson3$38
E.r. Squibb & Sons, L.L.C.3$36
Cequr Corporation1$32
Currax Pharmaceuticals LLC2$30
Ultragenyx Pharmaceutical Inc.2$29
Sunovion Pharmaceuticals Inc.1$20
Inspire Medical Systems, Inc.1$20
Sanofi1$19
Xeris Pharmaceuticals, Inc.1$18
Philips North America LLC1$18
Jazz Pharmaceuticals Inc.1$18
Scpharmaceuticals Inc.1$17
Idorsia Pharmaceuticals US Inc1$17
Nestle Healthcare Nutrition Inc.1$16
Antares Pharma, Inc.1$16
Tactile Systems Technology Inc1$15
Gilead1$14
Watermark Medical, Inc.1$14
Circassia Inc.1$13
Arbor Pharmaceuticals, Inc.1$12

How this compares

$7,840 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$212,792
Medicare patients
660
Services billed
2,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$87,681
OzempicSemaglutide74$84,554
EliquisApixaban71$73,764
FarxigaDapagliflozin Propanediol45$49,701
XareltoRivaroxaban40$46,316
Breo ElliptaFluticasone/Vilanterol46$35,785
MyrbetriqMirabegron59$35,742
SynthroidLevothyroxine Sodium306$29,518
TrulicityDulaglutide23$26,886
JanuviaSitagliptin Phosphate27$26,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$24,916
MounjaroTirzepatide22$21,166
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$21,108
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$15,946
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$12,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$636$96,67885 claims
Boehringer IngelheimJardiance$368$87,68166 claims
PfizerEliquis, Premarin, Abrysvo$304$84,43499 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$638$69,19182 claims
GSKBreo Ellipta, Trelegy Ellipta$296$60,70078 claims
Lilly USA, LLCTrulicity, Mounjaro$490$48,05245 claims
Johnson & JohnsonXarelto$38$46,31640 claims
AbbVieSynthroid, Linzess$1,118$41,102318 claims
MerckJanuvia, Janumet$231$38,28343 claims
Astellas Pharma US IncMyrbetriq$92$35,74259 claims
Sumitomo Pharma America, Inc.Gemtesa$62$11,96516 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$42$5,721583 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →